India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Thanks to lab-grown miniature intestines, researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Get Instant Summarized Text (Gist) Lab-grown human intestinal organoids enabled precise mapping of the genes Shigella bacteria require to invade and colonize human gut tissue. Of approximately ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International. The U.K. pharma company on Thursday said the agreement paves the way for the development ...